Welcome to our dedicated page for VAPOTHERM news (Ticker: VAPO), a resource for investors and traders seeking the latest updates and insights on VAPOTHERM stock.
Vapotherm, Inc. (OTCQX: VAPO) is a leading developer and manufacturer of advanced respiratory technology headquartered in Exeter, New Hampshire, USA. The company focuses on creating innovative, comfortable, and non-invasive technologies to support patients with chronic or acute breathing disorders. Over 4.4 million patients globally have benefited from Vapotherm's high-velocity therapy systems, including the HVT 2.0 and Precision Flow systems.
Vapotherm's core product, high-velocity therapy, is a mask-free, non-invasive ventilatory support tool that effectively relieves respiratory distress—including hypercapnia, hypoxemia, and dyspnea. This technology allows for the fast, safe treatment of undifferentiated respiratory distress with a single tool. The mask-free interface delivers optimally conditioned breathing gases, making it more comfortable for patients and reducing the risks associated with traditional mask therapies.
The company has shown significant sales growth and continues to invest in future growth drivers such as the HVT 2.0, clinical studies, and the upcoming Access365™ Home Ventilation Solution, anticipated to launch in early 2025. This new home ventilation solution aims to improve patient quality of life and reduce hospital readmissions for patients with respiratory diseases.
Financially, Vapotherm has made considerable strides in improving profitability. For example, in the third quarter of 2023, the company reported a net revenue increase of 12.0% over the previous year, attributed to rising capital and disposable demand, especially in international markets. Furthermore, gross profit and margin saw improvements, owing to effective inventory management and increased production efficiencies.
Despite challenges, such as delisting from the New York Stock Exchange and transitioning to the OTCQX Market, the company remains steadfast in its commitment to enhancing patient lives and maintaining significant market presence. Partnerships like the one with Onymos to develop a respiratory digital platform further underscore Vapotherm's dedication to innovation and improved patient outcomes.
Vapotherm, Inc. (NYSE: VAPO) reported 2021 revenue of $113.3 million, reflecting a 53% compounded annual growth rate over two years. The fourth quarter net revenue of $22.2 million represents a 45.6% decline from Q4 2020 due to decreased demand for Precision Flow units amid lower COVID-19 cases. Gross margin decreased to 35%, impacted by production costs. The company has a new debt facility providing up to $75 million to support operations. For 2022, revenue is projected between $104 million to $108 million, with a forecasted adjusted EBITDA loss of $39 million to $41 million.
Vapotherm, Inc. (NYSE: VAPO) will release its financial results for Q4 and the full year 2021 on February 24, 2022, after market close. A conference call will follow at 4:30 p.m. ET to discuss financial outcomes and recent developments. The company, based in Exeter, New Hampshire, focuses on innovative respiratory support technologies, treating over 3.2 million patients with its high velocity therapy systems, which are designed to relieve various forms of respiratory distress.
Vapotherm (NYSE: VAPO) announced preliminary unaudited revenue results for Q4 and full-year 2021, projecting $21.8 million for Q4 and $112.8 million for the year, reflecting compounded annual growth rates of 29% and 53%, respectively. CEO Joe Army highlighted the company's resilience amid COVID-19 challenges and supply chain issues, noting significant expansions in its U.S. customer base. For 2022, Vapotherm anticipates revenues between $104 million and $108 million, contingent on ongoing COVID-19 hospitalizations. Full financial results will be revealed in late February 2022.
Vapotherm, Inc. (NYSE: VAPO), a medical technology firm specializing in respiratory support, announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference. The fireside chat will take place on November 22, 2021, at 10:00 a.m. Eastern Time. Interested investors can access the presentation via Vapotherm's Investor website. Vapotherm's innovative high velocity therapy® systems have treated over 3.2 million patients with respiratory distress, providing non-invasive support through its unique Precision Flow system.
Vapotherm (NYSE: VAPO) reported third quarter 2021 revenue of $38.1 million, up 24.7% from Q3 2020, driven by a 66.2% increase in disposables revenue to $21.7 million. Despite increased demand linked to COVID-19, net loss widened to $13.6 million, or $0.52 per share. Operating expenses rose to $31.7 million, partly due to higher sales commissions. The company raised its fiscal 2021 revenue guidance to over $106 million, a 120% increase since 2019, while anticipating gross margins of 47% to 49%.
Vapotherm, Inc. (NYSE: VAPO) will release its financial results for Q3 2021 on November 3, 2021, after market close. The management team will hold a conference call at 4:30 p.m. ET to discuss results and recent business developments. U.S. callers can reach the call at (888) 330-2022, and international callers can dial +1 (646) 960-0690. The conference call will also be available via live webcast on the company's website, with a replay accessible for 90 days. Vapotherm focuses on non-invasive respiratory therapy for various breathing disorders.
Vapotherm, Inc. (NYSE: VAPO) has updated its fiscal year 2021 revenue expectations, now anticipating at least
Vapotherm (NYSE: VAPO) announced the 510(k) clearance from the US FDA for its HVT 2.0 system, designed for high-velocity therapy without requiring wall air. This innovation addresses a significant limitation, as an estimated 50% of U.S. hospital beds lack wall air. The company plans a limited commercial release in Q4 2021, which aims to enhance patient care by alleviating ICU bed shortages and reducing emergency room congestion. The HVT 2.0 is also integrated with the Vapotherm Access digital platform for home patient monitoring.
Vapotherm reported a 41% decline in second quarter 2021 revenue at $20.6 million compared to the same period in 2020, influenced by decreased demand related to COVID-19. Despite this, the company achieved a 72% revenue increase and a 31% CAGR over Q2 2019. The installed base of Precision Flow Hi-VNI systems grew to over 32,000 units. Net loss widened to $17.3 million, or $0.67 per share, while cash stood at $81.5 million. The company expects full-year revenue between $85 million and $91 million, reflecting an 83% increase over 2019.
Vapotherm (NYSE: VAPO), a medical technology leader, will present at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 10:00 am ET via webcast. The company's proprietary high velocity therapy® products are crucial for treating respiratory distress in patients of all ages. Interested parties can access the live presentation here. A replay will be available for 90 days post-event on Vapotherm's Investor website. Vapotherm's technologies support over 2.8 million treated patients, focusing on non-invasive respiratory care.
FAQ
What is the current stock price of VAPOTHERM (VAPO)?
What is the market cap of VAPOTHERM (VAPO)?
What does Vapotherm, Inc. specialize in?
What are Vapotherm's core products?
How many patients have been treated with Vapotherm's technology?
Where is Vapotherm headquartered?
What financial progress has Vapotherm made recently?
What is Vapotherm's Access365 Home Ventilation Solution?
What challenges has Vapotherm faced recently?
What recent partnerships has Vapotherm formed?
What upcoming product launches does Vapotherm have?
How does Vapotherm's high-velocity therapy benefit patients?
